Order results by:
Issue | Title | |
Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
A. V. Rudakova | ||
"... that apixaban was projected to increase life expectancy of the patients with NVAF compared with standards ..." | ||
Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
A. V. Rudakova, V. A. Parfenov | ||
"... in patients with NVAF in the Russian Federation. Aim. To evaluate the cost-effectiveness ratio of apixaban ..." | ||
Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
"... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..." | ||
Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
"... Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial ..." | ||
Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
A. V. Rudakova | ||
"... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
O. V. Shatalova | ||
"... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..." | ||
Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
"... неклапанной фибрилляции предсердий, об особенностях антикоагулянтной терапии при данной патологии и трудностях ..." | ||
Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
"... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..." | ||
Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
"... рекомендаций Европейской ассоциации сердечного ритма 2015 г. по применению НОАК у пациентов с неклапанной ..." | ||
Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
"... рекомендаций Европейской ассоциации сердечного ритма 2015 года по применению НОАК у пациентов с неклапанной ..." | ||
Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
"... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..." | ||
Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
"... предсердий неклапанной этиологии и ХБП. Анализируется возможность максимально безопасного применения ..." | ||
Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
Yu. A. Bunin, S. V. Miklishanskaya | ||
"... составляет 1-2%. Неклапанная ФП увеличивает риск развития ишемического инсульта в 5-7 раз. Более 50 ..." | ||
Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
"... ) and rs4148738 (c.2692-2236C>T) genes on the plasma concentration of apixaban, on changes in prothrombin ..." | ||
Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..." | ||
Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
"... Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban ..." | ||
Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
Company Pfizer | ||
"... неклапанной фибрилляции предсердий и острым коронарным синдромом и/или чрескожным коронарным вмешательством ..." | ||
Vol 12, No 3 (2016) | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE | Abstract PDF (Eng) similar documents |
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko | ||
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..." | ||
Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
"... длительного лечения ривароксабаном при неклапанной фибрилляции предсердий (ФП) и венозных тромбоэмболических ..." | ||
Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
S. N. Bel'diev | ||
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..." | ||
Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
Z. M. Safiullina, S. V. Shalaev | ||
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
Vol 10, No 3 (2014) | EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION | Abstract similar documents |
"... European Medicines Agency approved apixaban use in cardioversion. ..." | ||
Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..." | ||
Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
B. A. Tatarsky, N. V. Kazennova | ||
"... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
A. V. Rudakova | ||
"... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..." | ||
Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
S. R. Gilyarevsky | ||
"... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
"... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..." | ||
Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..." | ||
Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
D. A. Napalkov, A. A. Sokolova | ||
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..." | ||
Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
N. A. Novikova, A. N. Volovchenko | ||
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..." | ||
Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
"... .6%) started or continued taking rivaroxaban 20 mg 1 time/day and 3 (4.4%) started or continued taking apixaban ..." | ||
Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..." | ||
Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
"... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
S. R. Gilyarevskiy | ||
Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
T. V. Pavlova | ||
Vol 15, No 4 (2019) | Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen | Abstract similar documents |
A. I. Kochetkov, O. D. Ostroumova | ||
"... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..." | ||
Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
O. D. Ostroumova, I. V. Goloborodova | ||
Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
I. S. Yavelov | ||
Vol 15, No 5 (2019) | Findings Released from NAXOS Analysis. Pfizer Company Press Release | Abstract similar documents |
article Editorial | ||
"... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..." | ||
Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
S. V. Moiseev | ||
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
Vol 7, No 6 (2011) | DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER | Abstract similar documents |
I. S. Yavelov | ||
"... неклапанной фибрилляции предсердий. С учетом результатов крупного рандомизированного клинического исследования ..." | ||
Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
A. V. Rudakova | ||
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..." | ||
Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
"... -valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods ..." | ||
Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
"... фармакоэкономическую эффективность применения дабигатрана этексилата в сравнении с варфарином в профилактике сердечно ..." | ||
Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
S. Yu. Martsevich, Y. V. Lukina | ||
"... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
N. M. Vorobyeva, O. N. Tkacheva | ||
"... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
Vol 8, No 2 (2012) | COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION | Abstract similar documents |
O. P. Bobrova, M. M. Petrova | ||
"... Цель. Изучить фармакокинетические, фармакодинамические и фармакоэкономические показатели ..." | ||
Vol 4, No 4 (2008) | ECONOMIC REASONS FOR GENERIC CHOICE | Abstract similar documents |
N. P. Kutishenko, S. Y. Martsevich, S. N. Tolpygina, J. V. Lukina | ||
"... дженериков и оригинального препарата проведена фармакоэкономическая оценка изучаемых препаратов. ..." | ||
Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
К. V. Lobastov, I. V. Schastlivtsev | ||
"... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..." | ||
Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..." | ||
Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
S. Yu. Martsevich | ||
"... is inferior to apixaban in its ability to prevent ischemic stroke and systemic embolism and is more likely ..." | ||
Vol 7, No 1 (2011) | THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY | Abstract similar documents |
S. Yu. Martsevich, N. A. Dmitrieva, A. D. Deev, Yu. V. Lukina, L. A. Sokolova, V. V. Yakusevich | ||
Vol 6, No 4 (2010) | PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY) | Abstract similar documents |
S. Y. Martsevich, N. P. Kutishenko, A. D. Deev, S. A. Shalnova, R. G. Oganov | ||
"... Цель. Провести фармакоэкономический анализ «затраты-эффективность» терапии артериальной гипертонии ..." | ||
Vol 6, No 6 (2010) | EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER) | Abstract similar documents |
T. A. Istomina, E. V. Serdechnaya, L. A. Kulminskaya, B. A. Tatarskiy, E. V. Kazakevich, V. L. Lipskiy, S. I. Martyushov | ||
Vol 10, No 4 (2014) | PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE | Abstract similar documents |
E. I. Tarlovskaya, Y. A. Balandina, N. S. Maximchuk-Kolobova | ||
"... Цель. Фармакоэкономический анализ двух комбинаций препаратов, в состав которых входят ингибитор ..." | ||
Vol 8, No 1 (2012) | CHANGES IN THE COSTS OF HYPERTENSIVE CRISIS THERAPY DUE TO OPTIMIZATION OF DRUG SUPPLY IN THE PRE-ADMISSION CARE | Abstract similar documents |
N. I. Gaponova, N. F. Plavunov, V. L. Baratashvili | ||
Vol 9, No 1 (2013) | PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review | Abstract similar documents |
T. S. Romanenko, A. V. Kontsevaya, S. V. Fitilev | ||
"... Представлен обзор фармакоэпидемиологических и фармакоэкономических исследований антигипертензивной ..." | ||
Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
O. V. Averkov, L. N. Mishchenko | ||
"... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
Vol 6, No 4 (2010) | ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS | Abstract similar documents |
A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov | ||
"... осложнений, ассоциированных с неклапанной фибрилляцией предсердий, в частности ишемического инсульта. В ..." | ||
Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
"... among anticoagulants (36.7%). About a third of respondents were prescribed apixaban by a doctor (30 ..." | ||
Vol 19, No 2 (2023) | Left Atrial Thrombosis before Catheter Ablation or Cardioversion in Patients with Non-valvular Atrial Fibrillation or Atrial Flutter: what Risk Score is Most Informative? | Abstract similar documents |
I. A. Zaigraev, I. S. Yavelov, O. M. Drapkina, E. V. Bazaeva | ||
"... аблацией (КА) или кардиоверсией (КВ) у больных с неклапанной фибрилляцией (нФП) или трепетанием предсердий ..." | ||
Vol 10, No 2 (2014) | SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT | Abstract similar documents |
E. A. Drozdova | ||
"... . Рассматриваются актуальные проблемы ведения больных с инсультами, возникшими на фоне неклапанной фибрилляции ..." | ||
Vol 10, No 4 (2014) | MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
E. A. Belikov, K. V. Davtyan, O. N. Tkacheva | ||
Vol 21, No 1 (2025) | Practical aspects of perioperative management in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants | Abstract similar documents |
E. N. Markova, T. Yu. Vedenikin, A. A. Kuzub, N. V. Kuchieva, A. R. Navasardyan, O. N. Dzhioeva | ||
"... Статья посвящена периоперационному ведению пациентов с неклапанной фибрилляцией предсердий ..." | ||
Vol 7, No 5 (2011) | ECONOMIC BENEFITS OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION | Abstract similar documents |
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchicova, M. V. Avksentieva, I. E. Sapozhnikova, Y. A. Balandina | ||
"... фиксированной комбинации амлодипин/валсартан имеет не только клинические, но и фармакоэкономические преимущества ..." | ||
Vol 16, No 5 (2020) | Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY) | Abstract similar documents |
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko | ||
"... фармакоэкономическую оценку применения воспроизведенных препаратов статинов у больных высокого и очень высокого ..." | ||
Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
"... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..." | ||
Vol 16, No 4 (2020) | Real-Life International Normalized Ratio Profile in Patients with Non-Valvular Atrial Fibrillation Prescribed Vitamin K Antagonist | Abstract PDF (Eng) similar documents |
S. I. Farag, O. S. Arafa, A.A. E. Hassan, H. M. Mashhour, A. M. Bendary | ||
"... методы. В исследование включено 200 пациентов с неклапанной фибрилляцией предсердий, получающих ..." | ||
Vol 9, No 3 (2013) | ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION BY MARKOV’S MODELING | Abstract similar documents |
N. S. Maksimchuk-Kolobova, E. I. Tarlovskaya, S. V. Malchikova | ||
Vol 10, No 4 (2014) | RATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIA | Abstract similar documents |
T. Vekov | ||
"... Рассмотрены теоретические основы использования фармакоэкономического анализа для оценки ..." | ||
Vol 8, No 3 (2012) | PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY | Abstract similar documents |
A. V. Rudakova, M. S. Berezhnova | ||
"... . Заключение. Терапия варениклином пациентов со стенокардией является фармакоэкономически высокоэффективной как ..." | ||
Vol 8, No 2 (2012) | PRELIMINARY RESULTS OF COMPARATIVE PHARMACOECONOMIC PROSPECTIVE STUDY OF DIFFERENT THERAPIES OF ARTERIAL HYPERTENSION | Abstract similar documents |
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchikova, M. V. Avksentieva | ||
"... Цель. Провести сравнительный фармакоэкономический анализ двух различных вариантов ..." | ||
Vol 14, No 2 (2018) | PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS | Abstract similar documents |
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov | ||
"... благоприятного влияния на течение коморбидного сахарного диабета (СД). Однако вопрос о фармакоэкономических ..." | ||
Vol 12, No 1 (2016) | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease | Abstract similar documents |
E. I. Tarlovskaya, T. I. Chudinovskikh | ||
"... бисопролола. Фармакоэкономический анализ выявил, что для урежения ЧСС более выгодным с экономической точки ..." | ||
Vol 8, No 6 (2012) | HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
S. V. Moiseev | ||
"... у 18000 пациентов с неклапанной фибрилляцией предсердий (ФП) дабигатран в дозе 150 мг два раза в ..." | ||
Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
"... системных тромбоэмболических осложнений (ТЭО), кровотечений у пациентов с неклапанной фибрилляцией ..." | ||
Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
"... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
Vol 6, No 1 (2010) | SOME ASPECTS OF THE LISINOPRIL USAGE IN ARTERIAL HYPERTENSION TREATMENT | Abstract similar documents |
N. A. Jaiani | ||
"... , рассматриваются фармакоэкономические аспекты применения лизиноприла при артериальной гипертонии. ..." | ||
Vol 12, No 4 (2016) | New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) | Abstract similar documents |
Article Editorial | ||
"... пациентов с фибрилляцией предсердий неклапанного генеза. Эти результаты дополняют и вновь подтверждают ..." | ||
Vol 12, No 4 (2016) | Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation | Abstract similar documents |
S. G. Kanorskii | ||
"... обычной клинической практике у пациентов с неклапанной фибрилляцией предсердий. У последовательных ..." | ||
Vol 15, No 1 (2019) | Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation | Abstract similar documents |
V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko | ||
"... предсердий (ФП) неклапанной этиологии, госпитализированных в кардиологическое отделение многопрофильного ..." | ||
Vol 14, No 4 (2018) | Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice | Abstract similar documents |
N. M. Vorobyeva, O. N. kacheva | ||
"... неклапанной фибрилляцией предсердий. Приводятся результаты рандомизированного исследования ROCKET-AF, включая ..." | ||
Vol 17, No 6 (2021) | Changes in Prescribing Antithrombotic Therapy in Patients with Atrial Fibrillation in the Multidisciplinary Hospital in Volgograd from 2012 to 2020 | Abstract similar documents |
A. S. Gerasimenko, O. V. Shatalova, V. S. Gorbatenko, V. I. Petrov | ||
"... Цель. Изучить структуру назначения антитромботической терапии у пациентов с неклапанной ..." | ||
Vol 5, No 5 (2009) | THE COMPARATIVE COST-EFFICACY ANALYSIS OF VARIOUS ANTIHYPERTENSIVE THERAPIES | Abstract similar documents |
S. V. Malchikova, E. I. Tarlovskaya | ||
"... С - амлодипин и лизиноприл; группа D -амлодипин и бисопролол. Для фармакоэкономического анализа ..." | ||
Vol 15, No 2 (2019) | Cardiovascular medicine prices as an indicator of access to medicines and their rational use | Abstract similar documents |
C M. Razzakova, L. E. Ziganshina | ||
"... фармакоэкономическую оценку прямых затрат пациентов на лекарства для лечения артериальной гипертензии в 2015 г Для ..." | ||
Vol 12, No 3 (2016) | THE PREDICTION OF ATRIAL FIBRILLATION RECURRENCE AT VARIOUS METHODS OF SINUS RHYTHM RECOVERY | Abstract PDF (Eng) similar documents |
T. Y. Gromyko, S. A. Sayganov | ||
"... восстановления синусового ритма. Материал и методы. Обследовано 153 пациента с неклапанной формой ФП ..." | ||
1 - 100 of 117 Items | 1 2 > >> |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)